SynAct Pharma (SYNACT) investor relations material

Executive summary

• Positioned for a pivotal year with the completion of patient dosing in the Phase 2b ADVANCE study for resomelagon in RA; topline data expected in June 2026.

• Strengthened financial position through a SEK 51.9 million directed share issue, extending cash runway beyond key clinical milestones.

• Increased engagement with potential strategic partners and expanded business development activities ahead of anticipated data readout.

• Ongoing clinical programs in RA, viral infections, and polymyalgia rheumatica, with additional studies in nephrotic syndrome.

Financial highlights

• Net sales remained at SEK 0 for Q1 2026, consistent with the same period last year.

• Operating expenses increased 9% year-over-year to SEK 30,558 thousand.

• Loss after tax was SEK 25,487 thousand, slightly higher than SEK 24,684 thousand in Q1 2025.

• Earnings per share improved to -0.48 SEK from -0.51 SEK year-over-year.

• Cash flow from operating activities was SEK -32,952 thousand; cash and cash equivalents at period end were SEK 65,782 thousand.

Outlook and guidance

• Sufficient cash to fund operations and development activities for at least 12 months forward.

• Topline results from the ADVANCE Phase 2b study in RA expected in June 2026, anticipated as a major catalyst for business development and potential partnerships.

• Ongoing recruitment in RESOVIR-2 (Dengue) and RESPIRE (respiratory viral infections) studies, with further momentum expected in Q2 2026.